N-(tert-butoxycarbonyl)phenylglycine | 177712-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(tert-butoxycarbonyl)phenylglycine
• 英文别名: N2-(1,1-dimethylethoxycarbonyl)-D,L-phenylglycine；(L)-N-α-tert-butoxycarbonylphenylglycine；N-tert-butyloxycarbonyl-D-(-)-phenylglycine；N-(tert-butoxycarbonyl)-(S)-phenylglycine；N-tert-butyloxycarbonyl-(L)-phenylglycine；N-tert-butyloxycarbonyl-L-phenylglycine；2-[2-[(2-Methylpropan-2-yl)oxycarbonyl]anilino]acetic acid
• CAS: 177712-17-3
• 化学式: C₁₃H₁₇NO₄
• 分子量: 251.282
• InChiKey: IUDPWUPNTMTHBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl)phenylglycine 在 氯甲酸乙酯 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 17.17h， 生成 1-(2-carboxyphenyl)-3-(4-chlorobenzenesulfonyl)-imidazolidin-2,4-dione
  参考文献：
  名称：

  Substituted 3-(Phenylsulfonyl)-1-phenylimidazolidine-2,4-dione Derivatives as Novel Nonpeptide Inhibitors of Human Heart Chymase

  摘要：

  A series of 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives have been synthesized and evaluated for their ability to selectively inhibit human heart chymase. The structure-activity relationship studies on these compounds gave the following results. The 1-phenyl moiety participates in a hydrophobic interaction where an optimum size is required. At this position, 3,4-dimethylphenyl is the best moiety for inhibiting chymase and showed high selectivity compared with chymotrypsin and cathepsin G. A 3-phenylsulfonyl moiety substituted with hydrogen-bond accepters such as nitrile and methoxycarbonyl enhances its activity. Molecular-modeling studies on the interaction of 3-[(4-chlorophenyl)sulfonyl]-1-(4-chlorophenyl)imidazolidine-2,4-dione (29) with the active site of human heart chymase suggested that the 1-phenyl moiety interacts with the hydrophobic P-1 pocket, the 3-phenylsulfonyl moiety resides in the S-1'-S-2' subsites, and the 4-carbonyl of the imidazolidine ring and sulfonyl group interact with the oxyanion hole and the His-45 side chain of chymase, respectively. The complex model is consistent with the structure-activity relationships.

  DOI：

  10.1021/jm960793t
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 N-苯基甘氨酸 、 柠檬酸 在 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 生成 N-(tert-butoxycarbonyl)phenylglycine
  参考文献：
  名称：

  EP1211249

  摘要：

  公开号：

文献信息

• [EN] PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2011163518A1

  公开（公告）日：2011-12-29

  The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

  本发明提供了公式I或公式II的化合物：(I)、(II)或其药用可接受的盐或酯，如本文所述。这些化合物及其组合物可用于治疗副粘病毒感染。这些化合物、组合物和方法特别适用于治疗人类呼吸道合胞病毒感染。
• 6- or 7-beta-[2-[4-(substituted)-2,3-dioxopiperazin-1-yl) carbonylamino]-(substituted)acetamido]-penicillin and cephalosporin derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0293532A1

  公开（公告）日：1988-12-07

  Antibacterial agents have the formula (I) or are pharmaceutically acceptable salts or in vivo hydrolysable esters thereof: in which Y¹ is oxygen, sulphur or -CH₂ and Z represents hydrogen, halogen, C1-4 alkoxy, -CH₂-Q or -CH=CH-Q where Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carboxylic ester, C1-4 alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via nitrogen; R⁵ represents phenyl, substituted phenyl, cyclohexenyl, cyclohexadienyl or an optionally substituted 5 or 6-membered heterocyclic ring containing up to three hetero atoms selected from oxygen, sulphur or nitrogen, R⁶ is hydrogen, hydroxymethyl, formamido, or methoxy, R⁷ and R⁸ are the same or different and represent hydrogen, C1-6 alkyl, substituted C1-6 alkyl, halogen, amino, phenyl, substituted phenyl, hydroxy or C1-6 alkoxy or R⁷ and R⁸ form the residue of an optionally substituted 5 or 6- membered carbocyclic ring or a 5 or 6-membered heterocyclic ring containing up to three hetero atoms selected from oxygen, sulphur or nitrogen, R⁹ is wherein R¹⁰ and R¹¹ are the same or different and each represents hydroxy, or protected hydroxy and XR⁹ is -(CH₂)nR⁹, -NHCOR⁹, -N=CHR⁹, -NHCH₂R⁹, or -COR⁹, where n is from 0 to 2; with the proviso that XR⁹ does not represent -N=CHR⁹ when R⁶ represents hydrogen. The use of the compounds is described together with intermediates for their preparation.

  抗菌剂的化学式为（I），或者是其药用可接受盐或体内水解酯： 其中Y¹为氧、硫或-CH₂，Z代表氢、卤素、C1-4烷氧基、-CH₂-Q或-CH=CH-Q，其中Q代表氢、卤素、羟基、巯基、氰基、羧基、羧酸酯、C1-4烷氧基、酰氧基、芳基、通过碳键合的杂环基、杂环硫基或通过氮键合的含氮杂环基； R⁵代表苯基、取代苯基、环己烯基、环己二烯基或一个可选择取代的含有最多三个氧、硫或氮杂原子的5或6元杂环环，R⁶为氢、羟甲基、甲酰胺基或甲氧基，R⁷和R⁸相同或不同，代表氢、C1-6烷基、取代C1-6烷基、卤素、氨基、苯基、取代苯基、羟基或C1-6烷氧基，或R⁷和R⁸形成一个可选择取代的5或6元碳环或一个含有最多三个氧、硫或氮杂原子的5或6元杂环环，R⁹为 其中R¹⁰和R¹¹相同或不同，每个代表羟基或保护羟基，XR⁹为-(CH₂)nR⁹、-NHCOR⁹、-N=CHR⁹、-NHCH₂R⁹或-COR⁹，其中n为0至2；但XR⁹不代表-N=CHR⁹当R⁶代表氢时。 描述了这些化合物的用途以及其制备的中间体。
• [EN] MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS<br/>[FR] DERIVES DE MALONAMIDE UTILISES COMME INHIBITEURS DE LA GAMMA-SECRETASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004069826A1

  公开（公告）日：2004-08-19

  The invention relates to malonamide derivatives of formula (IA) or (IB) and to pharmaceutically suitable acid addition salts thereof. The compounds are Ϝ-secretase inhibitors and the related compounds may be useful in the treatment of Alzheimer's disease.

  这项发明涉及公式（IA）或（IB）的马隆酰胺衍生物及其药用适宜的酸盐。这些化合物是Ϝ-分泌酶抑制剂，相关化合物可能在治疗阿尔茨海默病方面有用。
• Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
  申请人：HALLEY Frank

  公开号：US20090082379A1

  公开（公告）日：2009-03-26

  Compounds of formula (I): wherein Ra, Rb, R, X 1 and X 2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

  式(I)的化合物： 其中Ra、Rb、R、X1和X2如所定义，提供了包括所述化合物的药物组合物、制备过程和使用方法。
• [EN] ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES<br/>[FR] COMPOSÉS ANTI-PCSK9 ET MÉTHODES DE TRAITEMENT ET/OU DE PRÉVENTION DE MALADIES CARDIO-VASCULAIRES
  申请人：SHIFA BIOMEDICAL CORP

  公开号：WO2014150395A1

  公开（公告）日：2014-09-25

  Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

  揭示了调节前蛋白酶转化亚硫酸酯酶基因型9（PCSK9）生理作用的化合物，以及利用这些调节剂降低低密度脂蛋白胆固醇水平和/或用于治疗和/或预防心血管疾病（CVD），包括治疗高胆固醇血症的方法。